Summary
The pharmacokinetics of salicyl phenolic glucuronide (SPG) and other salicylic acid (SA) metabolites were studied at three aspirin dosage regimens in eight patients with rheumatoid arthritis. Each patient received 1, 2 and 4 g enteric coated aspirin (ASA) daily in ascending order. At the end of each 2-week dosage period, plasma and urine were collected over a dosage interval for the estimation of various pharmacokinetic parameters. With increasing ASA dosage, mean clearance of SA to SPG was approximately constant (1.8±0.3, 1.7±0.2, and 1.5±0.2 ml/min at 1, 2 and 4 g/day, respectively) when related to plasma concentrations of total SA. The percentage of the ASA dosage recovered in urine as SPG increased from 5.2±1.1 to 7.1±1.1 to 10.5±1.7 at 1, 2 and 4 g/day, respectively. It was concluded, however, that the conversion of SA to SPG is saturable, since the mean clearance of SA to SPG decreased when calculated with respect of the plasma concentration of unbound SA (13.4±1.6, 11.0±1.4, and 6.6±1.9 ml/min at 1, 2 and 4 g/day, respectively). The kinetics of the formation and excretion of salicylurate and the excretion of gentisate were similar to those found in previous studies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bedford C, Cummings AJ, Martin BK (1965) A kinetic study of the elimination of salicylate in man. Br J Pharmacol 24: 418–431
Bochner F, Graham GG, Cham BE, Imhoff DM, Haavisto TM (1981) Salicylate metabolite kinetics after several salicylates. Clin Pharmacol Ther 30: 266–275
Levy G, Amsel LP, Elliott HC (1969) Kinetics of salicyluric acid elimination in man. J Pharm Sci 58: 827–829
Levy G, Tsuchiya T, Amsel LP (1972) Limited capacity for salicyl phenolic glucuronide formation and its effect on the kinetics of salicylate elimination in man. Clin Pharmacol Ther 13: 258–268
Furst DE, Gupta N, Paulus HE (1977) Salicylate metabolism in twins. Evidence suggesting a genetic influence and induction of salicylurate formation. J Clin Invest 60: 32–42
Günsberg M, Bochner F, Graham G, Imhoff D, Parsons G, Cham B (1984) Disposition of and clinical response to salicylates in patients with rheumatoid disease. Clin Pharmacol Ther 35: 585–593
Tsuchiya T, Levy G (1972) Biotransformation of salicylic acid to its acyl and phenolic glucuronides in man. J Pharm Sci 61: 800–801
Day RO, Furst DE, Dromgoole SH, Paulus HE (1982) Decline in steady-state serum salicylic acid concentrations with time in normal volunteers given high dose aspirin. Aust NZ J Med 12: 557–558
Borgä O, Odar-Cederlöf I, Ringberger V-A, Norlin A (1976) Protein binding of salicylate in uremic and normal plasma. Clin Pharmacol Ther 20: 464–475
Ekstrand R, Alvan G, Borgä O (1979) Concentration dependent plasma protein binding of salicylate in rheumatoid patients. Clin Pharmacokinet 4: 137–143
Furst DE, Tozer TN, Melmon KL (1979) Salicylate clearance, the resultant of protein binding and metabolism. Clin Pharmacol Ther 26: 380–389
Wosilait WD (1976) Theoretical analysis of the binding of salicylate by human serum albumin: The relationship between free and bound drug and therapeutic levels. Eur J Clin Pharmacol 9: 285–290
Smith PK, Gleason HL, Stoll CG, Ogorzalek S (1946) Studies on the pharmacology of salicylates. J Pharmacol Exp Ther 87: 237–255
Imhoff DM, Reece PA, Dimitriades E, Ward AD, Bochner F (1986) Direct measurement of salicyl phenolic glucuronide in human urine. Ther Drug Monit 8: 321–325
Ropes MW, Bennett GA, Lobb S, Jacox R, Jessar RA (1959) Diagnostic criteria for rheumatoid arthritis. Ann Rheum Dis 18: 49–53
Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, Buchanan WW (1968) Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Quart J Med 147: 393–406
Cham BE, Johns D, Bochner F, Imhoff DM, Rowland M (1979) Simultaneous liquid-chromatographic quantitation of salicylic acid, salicyluric acid, and gentisic acid in plasma. Clin Chem 25: 1420–1425
Wilkinson GR, Shand DG (1975) Physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18: 377–390
Rowland M, Riegelman S (1968) Pharmacokinetics of acetylsalicylic acid and salicylic acid after intravenous administration in man. J Pharm Sci 57: 1313–1319
Levy G, Tsuchiya T (1972) Salicylate accumulation kinetics in man. N Engl J Med 287: 430–432
Portek I, Graham GG, Fleming A (1981) Enteric coated pelletized aspirin: gastrointestinal blood loss and bioavailability. Med J Aust 2: 39–40
Markiewicz A, Semenowicz K (1979) Time dependent changes in the pharmacokinetics of aspirin. Int J Clin Pharmacol Biopharm 17: 409–411
Mandelli M, Tognoni G (1980) Monitoring plasma concentrations of salicylate. Clin Pharmacokinet 5: 424–440
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bochner, F., Graham, G.G., Polverino, A. et al. Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis. Eur J Clin Pharmacol 32, 153–158 (1987). https://doi.org/10.1007/BF00542188
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00542188